Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference WALTHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Checkpoint Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims NEW YORK, April 27, 2020 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Checkpoint Therapeutics,...